GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Dynavax Technologies Corporation (DVAX) [hlAlert]

Rating:
Outperform
DVAX
up 39.46 %

Dynavax Technologies Corporation (DVAX) rated Outperform with price target $6 by Wedbush

Posted on: Thursday,  Mar 24, 2011  1:25 PM ET by Wedbush

Wedbush rated Outperform Dynavax Technologies Corporation (NASDAQ: DVAX) on 03/24/2011. Previously Wedbush rated Outperform Dynavax Technologies Corporation (NASDAQ: DVAX) on
05/13/2010., when the stock price was $20.40. Since then, Dynavax Technologies Corporation has gained 39.46% as of 01/27/2016's recent price of $28.45.
If you would have followed the previous Wedbush 's recommendation on DVAX, you would have gained 39.46% of your investment in 2085 days.

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/24/2011 1:25 PM Buy
None
26.70 60.00
as of 12/30/2011
1 Week up  0.60 %
1 Month up  6.75 %
3 Months up  78.49 %
1 YTD up  3.75 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/9/2010 9:25 AM Buy
None
21.20 80.00
5/13/2010 8:25 AM Buy
None
20.40 60.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy